On September 2, 2026 Treeline Biosciences, Inc. ("Treeline") reported a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-121, Treeline’s BCL6 degrader, in combination with Roche’s CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in separate combination cohorts for patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Treeline will sponsor and conduct the Phase 1 dose escalation and expansion study, and Roche will supply glofitamab and mosunetuzumab for specific expansion cohorts. Treeline expects to initiate combination dosing for these expansion cohorts in the fourth quarter of 2026.
"CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche," said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumor activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T- and B-cells."
Preclinical Data Support Combination Strategy
TLN-121 has demonstrated single-agent activity in an ongoing Phase 1 clinical trial, including complete responses, in late-line DLBCL, follicular lymphoma (FL), and T follicular helper peripheral T-cell lymphoma (TFH PTCL).
BCL6 is a transcriptional repressor that helps B-cell lymphomas evade immune attack by silencing genes important for effective T-cell interactions. In DLBCL cell lines, TLN-121 restored expression of T-cell-recruiting cytokines and immune synapse genes. Treeline investigated the combination of TLN-121 and T-cell immunotherapies in DLBCL mouse xenograft models that responded suboptimally to either component as a single agent. In an aggressive DLBCL model supplemented with human T-cells, combining TLN-121 with a CD20xCD3 bispecific antibody produced complete regressions in four of six mice, compared with zero of six for TLN-121 alone and one of five for the antibody alone. In an aggressive DLBCL xenograft model, combining TLN-121 with CD19 CAR-T cells shrank tumors in four of six mice and completely regressed tumors in two of six, compared with no tumor shrinkage or regression in any mice for TLN-121 or the CD19 CAR-T alone.
(Press release, Treeline Biosciences, SEP 2, 2026, View Source [SID1234670557])